Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 19, Number 7—July 2013
Letter

Campylobacter jejuni in Hospitalized Patients with Diarrhea, Kolkata, India

Piyali Mukherjee, T. Ramamurthy, Mihir K. Bhattacharya, K. Rajendran, and Asish K. MukhopadhyayComments to Author 
Author affiliations: Author affiliation: National Institute of Cholera and Enteric Diseases, Kolkata, India

Main Article

Figure

Antimicrobial drug susceptibility profile of 142 Campylobacter jejuni isolates, Kolkata, India, 2008–2010. Black bars, resistant; gray bars, intermediate resistance; white bars, susceptible. AMP, ampicillin; NAL, nalidixic acid; NOR, norfloxacin; ERY, erythromycin; GEN, gentamicin; TET, tetracycline; CIP, ciprofloxacin; OFX, ofloxacin; FZD, furazolidone; CHL, chloramphenicol; AZM, azithromycin; STR, streptomycin; TMP–SXT, trimethoprim–sulfamethoxazole.

Figure. . . Antimicrobial drug susceptibility profile of 142 Campylobacter jejuni isolates, Kolkata, India, 2008–2010. Black bars, resistant; gray bars, intermediate resistance; white bars, susceptible. AMP, ampicillin; NAL, nalidixic acid; NOR, norfloxacin; ERY, erythromycin; GEN, gentamicin; TET, tetracycline; CIP, ciprofloxacin; OFX, ofloxacin; FZD, furazolidone; CHL, chloramphenicol; AZM, azithromycin; STR, streptomycin; TMP–SXT, trimethoprim–sulfamethoxazole.

Main Article

Page created: May 24, 2013
Page updated: May 24, 2013
Page reviewed: May 24, 2013
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external